KYNTRA BIO, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Kyntra Bio reported Q2 2026 continuing operations net income of $12.0M ($2.96 per share) versus Q2 2025 loss of $13.7M, driven primarily by a $30.9M gain on deconsolidation of a subsidiary. Cash and equivalents stood at $95.7M as of June 30, 2026, expected to fund operations into 2028. Phase 2 trial of FG-3246 (CD46-targeting ADC) for mCRPC continues with interim analysis on track for Q4 2026; roxadustat Phase 3 protocol for LR-MDS finalized with goal to initiate registrational study in Q4 2026.
Why this rating
One-time $30.9M subsidiary deconsolidation gain masks underlying $17.6M operating loss (Q2). Core loss from operations worsening. Cash position ($95.7M, 4.6x company market cap) adequate but burning ~$8M/quarter in operations. Pipeline progress routine for biotech stage. Not material relative to size.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.